| 000 | 03273cam0a2200445 4500 | ||
|---|---|---|---|
| 001 | 6985 | ||
| 009 | 11881124X | ||
| 003 | http://www.sudoc.fr/11881124X | ||
| 005 | 20250630091724.0 | ||
| 010 |
_a9780471752158 _brel. |
||
| 010 |
_a0-471-75215-0 _brel. |
||
| 020 |
_aUS _b 2007017891 |
||
| 073 | 1 | _a9780471752158 | |
| 090 | _a6985 | ||
| 099 |
_tOUVR _zALEX19261 |
||
| 100 | _a20071029h20072007k y0frey50 ba | ||
| 101 | 0 |
_aeng _2639-2 |
|
| 102 | _aUS | ||
| 105 | _aa a 001yy | ||
| 106 | _ar | ||
| 181 |
_6z01 _ctxt _2rdacontent |
||
| 181 | 1 |
_6z01 _ai# _bxxxe## |
|
| 182 |
_6z01 _cn _2rdamedia |
||
| 182 | 1 |
_6z01 _an |
|
| 183 | 1 |
_6z01 _anga _2RDAfrCarrier |
|
| 200 | 0 |
_aThe art of drug synthesis _fedited by Douglas S. Johnson, Jie Jack Li |
|
| 214 | 0 |
_aHoboken (N.J.) _cWiley-Interscience |
|
| 214 | 4 | _dC 2007 | |
| 215 |
_a1 vol. (xv-276 p.) _cill. _d26 cm |
||
| 300 |
_aDescription bibliographique disponible à l'adresse _uhttp://www.loc.gov/catdir/enhancements/fy0739/2007017891-d.html |
||
| 320 | _aNotes bibliogr. Index | ||
| 359 | 2 |
_pP. 1 _bThe role of medicinal chemistry in drug discovery / John A. Lowe III _pP. 11 _bProcess research: how much? how soon? / Neal G. Anderson _pP. 31 _bAromatase inhibitors for breast cancer : exemestane (Aromasin), anastrozole (Arimidex), and letrozole (Femara) / Jie Jack Li _pP. 39 _bQuinolone antibiotics : levofloxacin (Levaquin), moxifloxacin (Avelox), gemifloxacin (Factive), and garenoxacin (T-3811) / Chris Limberakis _pP. 71 _bTriazole antifungals : itraconazole (Sporanox), fluconazole (Diflucan), voriconazole (Vfend), and fosfluconazole (Prodif) / Andrew S. Bell _pP. 83 _bNon-nucleoside HIV reverse transcriptase inhibitors / Arthur Harms _pP. 95 _bNeuraminidase inhibitors for influenza : oseltamivir phosphate (Tamiflu) and zanamivir (Relenza) / Douglas S. Johnson and Jie Jack Li _pP. 117 _bPeroxisome proliferator-activated receptor (PPAR) agonists for type 2 diabetes / Jin Li _pP. 129 _bAngiotensin AT1 antagonists for hypertension / Larry Yet _pP. 143 _bLeading ACE inhibitors for hypertension / Victor J. Cee and Edward J. Olhava _pP. 159 _bDihydropyridine calcium channel blockers for hypertension / Daniel P. Christen _pP. 169 _bSecond-generation HMG-CoA reductase inhibitors / Jeffrey A. Pfefferkorn _pP. 183 _bCholesterol absorption inhibitors: ezetimibe (zetia) / Stuart B. Rosenblum _pP. 199 _bDual selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) for depression / Marta Piñeiro-Núñez _pP. 215 _bGABA receptor agonists for insomnia : zolpidem (Ambien), zaleplon (Sonata), eszopiclone (Estorra, Lunesta), and indiplon / Peter R. Guzzo _pP. 225 _bLigands: neurontin (Gabapentin) and lyrica (Pregabalin) / Po-Wai Yuen _pP. 241 _bApproved treatments for attention deficit hyperactivity disorder : amphetamine (Adderall), methylphenidate (Ritalin), and atomoxetine (Straterra) / David L. Gray |
|
| 606 |
_3030891612 _aMédicaments _xConception technique _2rameau |
||
| 606 |
_3027797996 _aChimie pharmaceutique _2rameau |
||
| 606 |
_aDrugs _xDesign _2lc |
||
| 606 |
_aPharmaceutical chemistry _2lc |
||
| 606 | 2 |
_aChemistry, Pharmaceutical _xmethods _2mesh |
|
| 676 |
_a615.19 _v22 |
||
| 700 | 1 |
_3118811231 _aJohnson _bDouglas Scott _f1968-.... _4340 |
|
| 701 | 1 |
_3074496093 _aLi _bJie Jack _4340 |
|